Tag - TGTX

Developments

TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib

TG Therapeutics (NASDAQ:TGTX) received the FDA fast track designation for the ublituximab plus umbralisib for the treatment of chronic lymphocytic leukemia (CLL). Ublituximab is a glycoengineered anti-CD20 monoclonal...

October 21, 2020

Developments

TG Therapeutics umbralisib and ublituximab meet primary endpoint in Phase 3 leukemia trial

TG Therapeutics (NASDAQ:TGTX) reported positive topline results from its Phase 3 trial in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). The trial met its primary endpoint...

May 6, 2020

Developments

TG Therapeutics umbralisib meets primary endpoint in Phase 2b lymphoma trial

TG Therapeutics (NASDAQ:TGTX) reported the follicular lymphoma (FL) cohort of the its Phase 2b pivotal trial of umbralisib met the primary endpoint of overall response rate (ORR). The trial included 188 FL patients who...

October 29, 2019

Developments

TG Therapeutics presents new data from Phase 2 and 3 trials of ublituximab

TG Therapeutics (NASDAQ:TGTX) presented initial Phase 3 and updated Phase 2 data for ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (RMS). At the 35th Annual...

September 13, 2019

Developments

TG Therapeutics gets FDA’s orphan drug designation for umbralisib

TG Therapeutics (NASDAQ:TGTX) received the FDA’s orphan drug designation for its phosphoinositide-3-kinase delta inhibitor, umbralisib, for the treatment of patients with marginal zone lymphoma (MZL). MZL is a slow...

April 15, 2019

Tag - TGTX

TG Therapeutics gets FDA fast track designation for ublituximab plus umbralisib

TG Therapeutics umbralisib and ublituximab meet primary endpoint in Phase 3 leukemia trial

TG Therapeutics umbralisib meets primary endpoint in Phase 2b lymphoma trial

TG Therapeutics presents new data from Phase 2 and 3 trials of ublituximab

TG Therapeutics gets FDA’s orphan drug designation for umbralisib

General

More